Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Abdominoplasty
NCT06086444Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Countries
- 1
- Sponsor
- Poznan University of Medical Sciences
- Modality
- Small Molecules
- Drugs
- tranexamic acid
- Conditions
- hemorrhage
01
Overview
Phase 4, randomised, double-blind trial in hemorrhage comparing Placebo with Tranexamic acid (2 arms). Primary endpoint: Blood loss volume. Started Oct 2023; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo
Normal saline IV
Tranexamic acid
Tranexamic Acid 10mg/kg IV
03
Who it enrols
Adult patients (18-75 years) with ASA 1 or 2 scheduled for abdominoplasty, excluding those with BMI <20 or >35, history of thromboembolism, hematological disease, epilepsy, or recent use of aspirin/anticoagulants.
04
Endpoints
Primary
Blood loss volume
Secondary
Hemoglobin
D-dimer
Fibrinogen
Beyond the preview
Go deeper on NCT06086444.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086444.